Analysis of cases of adverse drug reactions in pediatrics
- Authors: Egiazaryan E.A.1, Kosova I.V.1, Kurashov M.M.1, Sotnikova L.I.1
-
Affiliations:
- People's Friendship University of Russia named after Patrice Lumumba
- Issue: Vol 73, No 4 (2024)
- Pages: 50-54
- Section: Organization and economy
- URL: https://journal-vniispk.ru/0367-3014/article/view/260019
- DOI: https://doi.org/10.29296/25419218-2024-04-07
- ID: 260019
Cite item
Open Access
Access granted
Subscription Access
Abstract
Introduction. Due to the fact that prescribing medications to pediatric patients is potentially associated with an increased risk of adverse reactions (AR) or lack of therapeutic efficacy, monitoring the effects of pharmacotherapy in the post-registration period in this group of patients is of particular interest. Many drugs prescribed to children are not approved for use in pediatrics, and there is insufficient evidence of their safety and effectiveness in this population. Detection and analysis of signals in pediatric practice is a very time-consuming process. The spontaneous reporting system organized in medical organizations will allow obtaining new information about the safety of drug use by pediatric patients and developing measures to reduce the risks associated with pharmacotherapy.
Objective: to analyze cases of adverse reactions in the use of drugs in pediatrics, identified by medical professionals.
Material and methods. Sociological study, which was attended by 70 doctors working in children's clinics in Moscow. An original questionnaire containing 20 questions was developed for the study.
Results. The results obtained indicate that progress in the treatment of children can’t be achieved without improving the pharmacovigilance system in reporting cases of adverse reactions in medical organizations.
Conclusion. A significant contribution to the solution of this problem can be made by healthcare workers by timely informing the authorized pharmacovigilance authorities about the complications of pharmacotherapy in pediatric patients.
Full Text
##article.viewOnOriginalSite##About the authors
Elizaveta A. Egiazaryan
People's Friendship University of Russia named after Patrice Lumumba
Author for correspondence.
Email: zarubina.liz@yandex.ru
ORCID iD: 0000-0002-1174-6735
assistant of the Department of Management and Economics of Pharmacy
Russian Federation, Mikluho-Maclaya st., 6, Moscow, 117198Irina V. Kosova
People's Friendship University of Russia named after Patrice Lumumba
Email: kosovaira@mail.ru
ORCID iD: 0000-0002-3352-7875
Professor of Department of Management and Economics of Pharmacy
Russian Federation, Mikluho-Maclaya st., 6, Moscow, 117198Maksim M. Kurashov
People's Friendship University of Russia named after Patrice Lumumba
Email: kurashov-mm@rudn.ru
ORCID iD: 0000-0002-0349-905X
Associate Professor of the Department of Management and Economics of Pharmacy
Russian Federation, Mikluho-Maclaya st., 6, Moscow, 117198Lyudmila I. Sotnikova
People's Friendship University of Russia named after Patrice Lumumba
Email: trubnikova-li@rudn.ru
ORCID iD: 0000-0003-1850-6440
assistant of the Department of Management and Economics of Pharmacy
Russian Federation, Mikluho-Maclaya st., 6, Moscow, 117198References
- Боровикова Е.А. Проблемы репортирования о случаях нежелательных реакций на лекарственные препараты медицинскими и фармацевтическими работниками. Производство отечественных лекарственных средств и фармацевтическое образование: ключевые тренды взаимодействия: материалы VII, Всероссийской научно-практической конференции. Москва, 18 декабря 2020. Москва: РУДН, 2020; 15–24. [Borovikova E.A. Problems of reporting cases of adverse drug reactions by medical and pharmaceutical workers. Proizvodstvo otechestvennykh lekarstvennykh sredstv i farmatsevticheskoe obrazovanie: klyuchevye trendy vzaimodeistviya: materialy VII, Vserossiiskoi nauchno-prakticheskoi konferentsii. Moskva, 18 dekabrya 2020. Moskva: RUDN, 2020; 15–24 (in Russian)].
- Leporini C., De Sarro C., Palleria C., Caccavo I., Piro B., Citraro R., De Sarro G. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy. Drug Safety. 2022; 45 (11): 1381–402. doi: 10.1007/s40264-022-01232-w;
- Bouquet É., Star K., Jonville-Béra A.P., Durrieu G. Pharmacovigilance in pediatrics. Therapie. 2018; 73 (2): 171–80. doi: 10.1016/j.therap.2017.11.012;
- Tomasi P.A., Egger G.F., Pallidis C., Saint-Raymond A. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation. Paediatr Drugs. 2017; 19 (6): 505–13. doi: 10.1007/s40272-017-0261-1;
- Leitzen S., Dubrall D., Toni I., Stingl J., Schulz M., Schmid M., Neubert A., Sachs B. Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019. PLoS One. 2021; 16 (3): e0247446. doi: 10.1371/journal.pone.0247446;
- Титова А.Р., Асецкая И.Л., Поливанов В.А., Зырянов С.К., Глаголев С.В. Мониторинг нежелательных реакций при применении лекарственных препаратов у детей в Российской Федерации. Педиатрия. 2017; 96 (3): 152–9. [Titova A.R., Asetskaya I.L., Polivanov V.A., Zyryanov S.K., Glagolev S.V. Monitoring of adverse reactions in the use of drugs in children in the Russian Federation. Pediatriya. 2017; 96 (3): 152–9. doi: 10.24110/0031-403X-2017-96-3-152-159 (in Russian)].
- Кутехова Г.В., Журавлева Е.О., Дармостукова М.А., Снегирева И.И., Вельц Н.Ю., Аляутдин Р.Н., Шубникова Е.В. Сигнальные сообщения в педиатрической практике. Безопасность и риск фармакотерапии. 2018; 6 (4): 180–6. [Kutekhova G.V., Zhuravleva E.O., Darmostukova M.A., Snegireva I.I., Vel'ts N.Yu., Alyautdin R.N., Shubnikova E.V. Signal reports in pediatric practice. Bezopasnost' i risk farmakoterapii. 2018; 6 (4): 180–6. doi: 10.30895/2312- 7821-2018-6-4-180-186 (in Russian)].
Supplementary files
